Diversified Trust Co Purchases 1,018 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Diversified Trust Co lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 23.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,401 shares of the medical equipment provider's stock after buying an additional 1,018 shares during the period. Diversified Trust Co's holdings in Intuitive Surgical were worth $2,675,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Onefund LLC raised its stake in shares of Intuitive Surgical by 1.9% in the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the last quarter. AlphaCore Capital LLC raised its stake in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after purchasing an additional 18 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Intuitive Surgical by 2.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock worth $390,000 after purchasing an additional 19 shares during the last quarter. Accredited Investors Inc. raised its stake in shares of Intuitive Surgical by 1.9% in the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock worth $543,000 after purchasing an additional 19 shares during the last quarter. Finally, Second Line Capital LLC raised its stake in shares of Intuitive Surgical by 3.4% in the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after purchasing an additional 19 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $0.48 during mid-day trading on Friday, reaching $533.71. The company's stock had a trading volume of 2,014,026 shares, compared to its average volume of 1,675,502. The firm has a market capitalization of $191.29 billion, a PE ratio of 78.26, a P/E/G ratio of 5.67 and a beta of 1.67. The stock has a fifty day moving average of $532.08 and a two-hundred day moving average of $536.80. Intuitive Surgical, Inc. has a 52 week low of $413.82 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter in the prior year, the company posted $1.50 earnings per share. Analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the transaction, the director now directly owns 6,371 shares of the company's stock, valued at approximately $3,312,920. This represents a 27.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 215 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $549.06, for a total value of $118,047.90. Following the transaction, the senior vice president now directly owns 1,768 shares of the company's stock, valued at approximately $970,738.08. The trade was a 10.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock valued at $2,611,577 over the last 90 days. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ISRG shares. Piper Sandler reduced their price objective on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on Intuitive Surgical and gave the company a "buy" rating in a research report on Monday, April 14th. Robert W. Baird reduced their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Royal Bank Of Canada reduced their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Finally, Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus price target of $588.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.